do not combine dpp-4 inhibitors with glp-1 receptor agonists recommendation DPP4 Inhibitor Mechanism of Action – My Endo Consult Table 2 from DPP- 4
Description
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
"Think 2025 Was a Big Year for Health News
Multiple studies have found many adults with CKD or at risk for CKD do not have urinary albumin-to-creatine ratio (UACR), a key biomarker for CKD, measured on an annual basis
Given emerging evidence of both metabolic and direct cardiovascular actions, a comprehensive synthesis of cardiovascular outcome trial data is required to clarify the efficacy and safety of this drug class
Post-matching survival analysis utilized Kaplan-Meier estimation, while treatment effects were quantified through Cox proportional hazards models, yielding hazard ratios (HRs) with 95% confidence intervals (CIs) and P values
